Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778293 | 0.84 | ALDH1A1 (0.46) | ALDH1A1GAASMN1; SMN2KDM4ECHRM2 | |
| SCHEMBL28750638 | 0.81 | ALDH1A1 (0.60) | ALDH1A1GAASMN1; SMN2KDM4ELMNA | |
| SCHEMBL6211339 | 0.77 | NR2F2 (0.47) | ALDH1A1GAASLC18A3NR2F2SMN1; SMN2 | |
| SCHEMBL6213917 | 0.77 | GAA (0.70) | ALDH1A1GAASMN1; SMN2KDM4ECHRM2 | |
| SCHEMBL5781757 | 0.75 | CHRM2 (0.39) | CHRM2CHRM3 | |
| SCHEMBL5780640 | 0.75 | ALDH1A1 (0.46) | ALDH1A1GAASLC18A3NR2F2SMN1; SMN2 | |
| SCHEMBL5782055 | 0.73 | CHRM2 (0.38) | CHRM2CHRM3 | |
| SCHEMBL5778158 | 0.71 | CACNA2D1 (0.39) | — | |
| SCHEMBL621714 | 0.71 | ALDH1A1 (0.58) | ALDH1A1GAASLC18A3NR2F2SMN1; SMN2 | |
| SCHEMBL5960277 | 0.70 | ALDH1A1 (0.68) | ALDH1A1GAASLC18A3NR2F2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | ALDH1A1 408/4885GAA 4386/4885SLC18A3 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.